Tarcocimab tedromer clinical trials
Also written KSI-301.
How each study uses tarcocimab tedromer is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Kodiak Sciences Inc (8)
Studies
Open first, then newest update. How each study uses tarcocimab tedromer is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKActive, not recruitingPhase 3Kodiak Sciences IncNCT06556368Written as Tarcocimab tedromer
- A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)TerminatedPhase 3Kodiak Sciences IncNCT05066230Written as KSI-301
- A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)TerminatedPhase 3Kodiak Sciences IncNCT04611152Written as KSI-301
- A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)TerminatedPhase 3Kodiak Sciences IncNCT04603937Written as KSI-301
- A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.TerminatedPhase 2/3Kodiak Sciences IncNCT04049266Written as KSI-301
- A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)CompletedPhase 3Kodiak Sciences IncNCT04964089Written as KSI-301
- A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)CompletedPhase 3Kodiak Sciences IncNCT04592419Written as KSI-301
- Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVOTerminatedPhase 1Kodiak Sciences IncNCT03790852Written as KSI-301
Codes
What other systems call tarcocimab tedromer · ClinicalTrials.gg INT015472
- UNII (FDA) 7HW5CX6OD5TARCOCIMAB TEDROMEROne source FDA
- NCI Thesaurus C188530Tarcocimab TedromerOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7HW5CX6OD5 | TARCOCIMAB TEDROMER | One source FDA |
| NCI Thesaurus | C188530 | Tarcocimab Tedromer | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.